Literature DB >> 18677456

[Pancreatic carcinoma].

M P Lutz1, S Pourebrahim.   

Abstract

Ductal adenocarcinomas represent over 90% of all pancreatic cancers. The high mortality has not changed over the last decades. Most patients are elderly and typically present with dull upper abdominal pain radiating to the back and often report reduced appetite, weight loss, and jaundice. A solid pancreatic tumor should be resected because this is the only chance for a cure. Cystic tumors are usually less malignant and need further diagnostic work-up. There is a benefit from adjuvant chemotherapy after resection. Locally advanced or metastatic tumors are treated symptomatically including pain medication and biliary drainage in the case of jaundice. There is a benefit from systemic chemotherapy mainly in patients with good performance status.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18677456     DOI: 10.1007/s00108-008-2203-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  11 in total

Review 1.  [Pathogenesis of the ductal pancreatic adenocarcinoma: implications for future therapies?].

Authors:  G Schneider; R M Schmid
Journal:  Internist (Berl)       Date:  2005-02       Impact factor: 0.743

2.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

3.  [S3-Guidelines "Exocrine pancreatic cancer" 2007].

Authors:  G Adler; T Seufferlein; S C Bischoff; H-J Brambs; S Feuerbach; G Grabenbauer; S Hahn; V Heinemann; W Hohenberger; J M Langrehr; M P Lutz; O Micke; H Neuhaus; P Neuhaus; H Oettle; P M Schlag; R Schmid; W Schmiegel; K Schlottmann; J Werner; B Wiedenmann; I Kopp
Journal:  Z Gastroenterol       Date:  2007-06       Impact factor: 2.000

4.  [CA 19-9 in the differential diagnosis of pancreatic lesions].

Authors:  S Stintzing; C Herold; E G Hahn; F Boxberger
Journal:  Internist (Berl)       Date:  2008-02       Impact factor: 0.743

5.  Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  Malcolm J Moore; David Goldstein; John Hamm; Arie Figer; Joel R Hecht; Steven Gallinger; Heather J Au; Pawel Murawa; David Walde; Robert A Wolff; Daniel Campos; Robert Lim; Keyue Ding; Gary Clark; Theodora Voskoglou-Nomikos; Mieke Ptasynski; Wendy Parulekar
Journal:  J Clin Oncol       Date:  2007-04-23       Impact factor: 44.544

Review 6.  Pancreatic cancer: a review of the evidence on causation.

Authors:  Andrew R Hart; Hugh Kennedy; Ian Harvey
Journal:  Clin Gastroenterol Hepatol       Date:  2008-03       Impact factor: 11.382

Review 7.  Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts.

Authors:  Georg Feldmann; Anirban Maitra
Journal:  J Mol Diagn       Date:  2008-02-07       Impact factor: 5.568

8.  Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer.

Authors:  D D Stocken; M W Büchler; C Dervenis; C Bassi; H Jeekel; J H G Klinkenbijl; K E Bakkevold; T Takada; H Amano; J P Neoptolemos
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

9.  Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies.

Authors:  R Huxley; A Ansary-Moghaddam; A Berrington de González; F Barzi; M Woodward
Journal:  Br J Cancer       Date:  2005-06-06       Impact factor: 7.640

10.  Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.

Authors:  Volker Heinemann; Stefan Boeck; Axel Hinke; Roberto Labianca; Christophe Louvet
Journal:  BMC Cancer       Date:  2008-03-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.